Sonnet Biotherapeutics Holdings Inc. has completed two IND-enabling toxicology studies in nonhuman primates (NHPs) using its lead bifunctional therapeutic candidate, SON-1210.

Equillium Inc. has advanced EQ-102, a first-in-class multi-cytokine inhibitor of IL-15 and IL-21 for celiac disease, into a phase I study in healthy volunteers.

Researchers around the world are making advances in understanding how HIV becomes latent and seeking out vulnerabilities that could provide routes to targeting reservoirs and eliminating them.

Askgene Pharma Inc., which less than two weeks ago reported positive initial data from an ongoing phase I/II trial testing its claudin 18.2-targeting candidate, ASKB-589, added $20 million in a series A round, intended to advance the company’s clinical pipeline and support further development of its Smartkine cytokine drug platform.

Askgene Pharma Inc., which less than two weeks ago reported positive initial data from an ongoing phase I/II trial testing its claudin 18.2-targeting candidate, ASKB-589, added $20 million in a series A round, intended to advance the company’s clinical pipeline and support further development of its Smartkine cytokine drug platform.